Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.

Christian MarthRafal TarnawskiAlexandra TyulyandinaSandro PignataLucy GilbertDiego KaenM Jesús RubioSophia FrentzasMario BeinerManuel Magallanes-MacielLaura FarrellyChel Hun ChoiRegina BergerChristine LeeChristof VulstekeKosei HasegawaElena Ioanna BraicuXiaohua WuJodi McKenzieJohn J LeeVicky Makker

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)

ClinicalTrials.gov, NCT03884101.

Keyphrases

endometrial cancer
open label
phase ii
phase iii
double blind
phase ii study
study protocol
placebo controlled
advanced non small cell lung cancer
radiation therapy
chemotherapy induced